Gilead Sciences stock after-hours at EUR 128.59: minus 0.01 percent versus prior close
Published on 10/05/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences was at EUR 128.59 after-hours at 8:30 p.m. CEST on October 5, 2026, down 0.01 percent versus the prior close at Lang & Schwarz.
Gilead Sciences stock after the Xetra close
The prior close at Lang & Schwarz was EUR 128.60. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Two-year extension for oncology research
GlobeNewswire reported on October 5, 2026, that Nurix Therapeutics and Gilead Sciences agreed to extend the research term for an undisclosed oncology program by two years. It is the second two-year extension for the program.
Under the collaboration, originally established in 2019, Gilead has an option to license resulting drug candidates. Nurix will receive a $10 million research-term extension fee, while the first program licensed by Gilead under the agreement, GS-6791, is in Phase 1 clinical development.
